163 related articles for article (PubMed ID: 6773974)
21. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Lønning PE; Johannessen DC; Thorsen T; Ekse D
J Steroid Biochem; 1989 Oct; 33(4A):541-5. PubMed ID: 2811363
[TBL] [Abstract][Full Text] [Related]
22. Aromatase inhibitors and the treatment of breast cancer.
Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
J Steroid Biochem; 1986 Jan; 24(1):91-7. PubMed ID: 3702431
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
[TBL] [Abstract][Full Text] [Related]
24. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Lønning PE; Dowsett M; Powles TJ
J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
[TBL] [Abstract][Full Text] [Related]
25. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
26. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
Dowsett M; Santner SJ; Santen RJ; Jeffcoate SL; Smith IE
Br J Cancer; 1985 Jul; 52(1):31-5. PubMed ID: 4015950
[TBL] [Abstract][Full Text] [Related]
27. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Kao YC; Okubo T; Sun XZ; Chen S
Anticancer Res; 1999; 19(3A):2049-56. PubMed ID: 10470147
[TBL] [Abstract][Full Text] [Related]
28. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
Usuki S; Kondoh K; Kubo T
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
[TBL] [Abstract][Full Text] [Related]
29. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
30. Regulation of gonadotropin secretion in the male dog. Role of estradiol.
Winter M; Falvo RE; Schanbacher BD; Verholtz S
J Androl; 1983; 4(5):319-23. PubMed ID: 6415027
[TBL] [Abstract][Full Text] [Related]
31. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
32. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
33. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
[TBL] [Abstract][Full Text] [Related]
34. Peripheral and not central suppression of ovarian function during osmotic pump infusion of adrenocorticotropin-(1-24) for one menstrual cycle in the cynomolgus monkey and its partial compensation by a transitory elevation of sex hormone-binding globulin levels.
Kowalski W; Chatterton RT
Endocrinology; 1992 Jun; 130(6):3582-92. PubMed ID: 1597155
[TBL] [Abstract][Full Text] [Related]
35. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
36. Effect of treatment with aromatase inhibitor 4-hydroxandrostenedione on the nonhuman primate menstrual cycle.
Brodie AM; Hammond JO; Ghosh M; Meyer K; Albrecht ED
Cancer Res; 1989 Sep; 49(17):4780-4. PubMed ID: 2758411
[TBL] [Abstract][Full Text] [Related]
37. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
38. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone.
Jannuzzo MG; Di Salle E; Spinelli R; Pirotta N; Buchan P; Bello A
Breast Cancer Res Treat; 2009 Feb; 113(3):491-9. PubMed ID: 18330698
[TBL] [Abstract][Full Text] [Related]
39. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
40. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels.
Geisler J; Haynes B; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2007 Apr; 104(1-2):27-34. PubMed ID: 17350249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
